A Japanese chemist came to America to reinvent whiskey. America answered him with fire — perhaps literally.
“Good wine is a good familiar creature, if it be well used,” Iago says in Act II of Othello, pouring Cassio another glass. The context, as is Shakespeare’s way, is poisonous: Iago gets his rival drunk so that he will lose face. Wine is a good creature, if properly used. But who decides what “properly” means? For Jokichi Takamine, born in Japan in 1854, the answer lay in a field neither Shakespeare nor his characters could have imagined: the biochemistry of industrial fermentation.
By the end of the 19th century, American whiskey production was a well-oiled machine. Grain — corn, rye, barley — was turned into alcohol through a chain in which every link had accumulated its own habits, equipment, and people. The crucial stage was saccharification: the grain’s starch had to be broken down into simple sugars so yeast could ferment them into alcohol. American distillers did this with malt — germinated barley whose own enzymes, amylases, did the work. The process required separate grain, separate rooms for germination, and control over temperature and humidity. Put crudely, to make whiskey from corn, you first had to grow barley, then make it germinate, then dry it — and only then put it to work. Takamine looked at this arrangement through the eyes of someone raised in a culture where the same problem had been solved differently for more than a thousand years.
In Japan, koji — rice or another grain inoculated with spores of the mold fungus Aspergillus oryzae — was used to make sake, soy sauce, and miso. As the fungus spread across the grain’s surface, it released powerful amylolytic enzymes that broke down starch faster and more thoroughly than malt enzymes did. No germination, no drying. The grain became both substrate and enzyme factory at once — an elegant economy, when you think about it. Takamine, educated in Tokyo and Glasgow, did think about it.
In September 1889, he received U.S. Patent No. 411,231 — “Process of the Manufacture of Alcoholic Liquids.” The document described the use of Aspergillus oryzae to saccharify grain in alcohol production. The figures claimed in the patent looked appealing: strength of up to 18%, while costs and production scale were cut to one-third of the usual. Malt became unnecessary. Separate malt houses — unnecessary. An entire stratum of barley suppliers — unnecessary. Takamine proposed replacing a living plant that had to be germinated with a dead fungus that merely had to be grown on grain. The difference may seem cosmetic, but for the industry it was tectonic.
In 1890, Takamine moved to Chicago and founded the Takamine Ferment Company. What wins me over about this decision is its confidence: a man from a country where the last generation of samurai was still alive arrives in a city of slaughterhouses and railroad magnates and says — I know how to make your whiskey better. Between 1891 and 1894, he secured his rights through a series of patents, including Patent No. 525,823 for the enzyme Taka-Diastase — the commercial name for an amylase derived from Aspergillus oryzae.
Takamine’s partner was the Distillers and Cattle Feeders Trust, known as the “Whiskey Trust” — a monopolistic combine controlling a substantial share of the American spirits market from its headquarters in Peoria, Illinois. Peoria — a city few people today associate with anything beyond the phrase “Will it play in Peoria?” — was, at the end of the 19th century, a nerve center of the liquor industry, a place where distilleries lined the Illinois River more densely than pubs line Dublin. The Whiskey Trust signed an exclusive agreement with Takamine: his enzyme method was to be tested at the Manhattan Distillery — according to some accounts in Peoria, according to others, in the town of Manhattan, Illinois.
The logic of the deal was transparent. The trust needed lower costs — monopolies love savings. Takamine needed scale — a patent without a factory remains paper. On paper, both got what they wanted.
A fire broke out at the Manhattan Distillery. Takamine’s installation burned down. Contemporaries suspected sabotage — and in the context of the era, those suspicions were not groundless. America’s liquor industry of the 1890s was not known for gentlemanly manners: the Whiskey Trust had already been accused of pressuring competitors by methods far removed from market competition. Maltsters, whose livelihoods depended directly on preserving the traditional technology, had an obvious motive. So did distillery workers accustomed to malt and unable to make sense of Japanese mold. But sabotage was never proven. The fire may have been an accident, it may have been arson, it may have resulted from the fact that an experimental installation was being hastily assembled inside an operating plant, where alcohol fumes were part of the air.
I am always wary when the only explanation for a collapse is a fire. It is too convenient a full stop: there was a project, then fire came, and the project was over. But Takamine ran into problems that do not burn. The American whiskey industry was built around malt as a structural element. Malt houses, barley suppliers, master maltsters, recipes designed around malt saccharification — all of it formed an ecosystem in which every participant depended on the others, and every participant had a stake in preserving the status quo. Even if the distillery had not burned down, Takamine would have had to convince an entire industry to throw decades of experience onto the scrap heap and start working with fungal mold that nobody in Peoria knew how to cultivate. A patent gives you legal rights. It does not give you infrastructure, skills, or trust.
In February 1895, the Whiskey Trust itself was placed into receivership — financial troubles compounded pressure from antitrust legislation (the Sherman Act, passed back in 1890, had finally caught up with the liquor monopoly). Takamine’s partner collapsed, and in May 1895 the chemist secured the termination of the exclusive contract — he was free now, but that freedom meant his technology had been left without an industrial foothold.
What happened next deserves admiration of its own. Takamine did not keep beating his head against the wall of the whiskey industry. He looked at his enzyme — Taka-Diastase, an amylase from Aspergillus oryzae — and saw in it not a tool for a distillery but a medicine. Amylase breaks down starch. The stomach of a person with dyspepsia does a poor job with starch. The logic was as straight as a railroad tie. By July 1895 — two months after the contract with the trust was terminated — Takamine, together with the pharmaceutical company Parke, Davis and Company, began selling Taka-Diastase as a remedy for stomach ailments. The drug proved commercially successful and was sold for decades.
The speed of that pivot is astonishing. A little more than a year passed between the fire in Peoria and the pharmacy counters. Takamine had, in essence, pulled off one of the early examples of what would today be called a startup “pivot” — except his startup was enzyme biotechnology at the end of the century before last.
In 1900, Takamine obtained pure crystals of adrenaline — a hormone of the adrenal glands whose existence was known, but which no one had managed to isolate in pure form. Patent applications were filed on November 5, 1900, and in 1901 the substance was presented to the medical community. Adrenaline became the first hormone isolated in crystalline form, and the first to enter industrial production. The man who began with mold on rice gave medicine a molecule without which no emergency resuscitation is possible today.
Takamine lived in America until the end of his life and left a mark visible to every tourist in Washington. He helped bring Japanese cherry trees (sakura) to the banks of the Potomac — the trees were officially planted in March 1912 with the participation of First Lady Helen Taft. The chemist who tried to change American whiskey ended up changing the American spring. On July 22, 1922, Takamine died at the age of 67.
Takamine’s forgotten whiskey technology now looks not like a failure, but like a discovery that came too early. Industrial enzymology — the use of isolated enzymes instead of whole organisms — became the foundation of modern production of ethanol, beer, bread, textiles, and detergents. Aspergillus oryzae, that same fungus Peoria rejected, was named Japan’s “national fungus” by the Brewing Society of Japan in 2006. And in recent years, craft distillers in the United States and Europe have increasingly been experimenting with koji — fermenting corn, barley, and rye with it, creating new flavor profiles the malt tradition never even suspected existed.
I like that the story came full circle in exactly this way. Takamine arrived in Peoria with his mold in 1891 and was rejected — by fire, inertia, the collapse of his partner. More than a century later, distillers themselves reached for koji, no longer out of a need to save money, but out of curiosity — the very thing it had all begun with, really. His 1889 patent described a process the industry proved ready to embrace only once it had forgotten who proposed it first.